Although statins, doxycycline, vitamin E, COX-2 inhibitors, angiotensin-converting enzyme inhibitors and Ang-II-receptor blockers have been suggested to reduce AAA expansion (Golledge et al., 2006; Samson, 2012; Dodd and Spence, 2011; Manning et al., 2003), none of these therapies has conclusively demonstrated their clinical benefit. The gene discussed is PTGS2; the disease is triple-A syndrome.